Daré Bioscience, Inc (DARE)

Trade DARE now with
12/7/2020 8:16:00 AM Daré Bioscience Phase 3 Trial Of DARE-BV1 Trial Met Its Primary Endpoint
9/1/2020 8:13:01 AM Daré Bioscience And Avomeen Sign Strategic Partnership
8/20/2020 8:10:05 AM Daré Bioscience Announces Publication Of DARE-BV1 Proof Of Concept Study For Bacterial Vaginosis
7/27/2020 8:22:53 AM Daré Bioscience Begins Phase 1 Clinical Trial Of DARE-HRT1
6/17/2020 8:15:34 AM Daré Bioscience Begins Pivotal Phase 3 Study Of DARE-BV1 In Patients With Bacterial Vaginosis
1/13/2020 9:36:24 AM Bayer Signs License Agreement With Daré Bioscience
1/13/2020 7:11:09 AM Bayer To Commercialize Dar Bioscience's Investigational contraceptive Product Ovaprene In The U.S. Once Approved By FDA
12/18/2019 8:10:42 AM Daré Bioscience Says FDA Cleared Its Investigational New Drug Application For DARE-BV1
11/11/2019 8:11:34 AM Daré Bioscience Agrees To Acquire Microchips Biotech
8/12/2019 8:08:59 AM Daré Bioscience Receives QIDP Designation From FDA For DARE-BV1
6/26/2019 8:23:27 AM Daré Bioscience Completes Recruitment In Pre-Pivotal Trial Of Ovaprene
11/29/2018 8:07:32 AM Daré Bioscience Announces Initiation Of Content Validity Study For Sildenafil Cream, 3.6%
9/17/2018 8:09:26 AM Daré Bioscience Appoints Greg Matz To Board
6/4/2018 8:09:45 AM Daré Bioscience Appoints Mary Jarosz To Newly Created Role Of Global Head Of Regulatory Affairs
5/15/2018 8:07:23 AM Daré Bioscience Announces Trial Initiation For Ovaprene Non-Hormonal Monthly Contraceptive Candidate